Eric Butz Email & Phone Number

Greater Seattle Area

The Cascadia Drug Development Group is comprised of seasoned industry experts in biomedical research and drug development. We offer a wide range of consulting expertise within a single integrated framework. CDDG also provides strategic planning and oversight of therapeutic development, from discovery to early clinical development. By offering a flexible and virtual structure we can easily adapt to client and project needs to meet the projects current and future needs and reduce overall costs. In this way, we enable a new and sustainable paradigm for therapeutic discovery by helping to rapidly and efficiently de-risk projects. We have worked with partners around the world to enable high quality, efficient drub development to maximize the value of therapeutics in immune-oncology, inflammatory disease and infectious disease indications.

Greater Seattle Area

As an immunology scientist with broad experience developing biologic and small molecule therapeutics at all stages of preclinical study I can provide support for data evaluation, scientific due diligence, and strategic planning for target selection, validation, preclinical studies and therapeutic development. My clients have included established and start up biopharmaceutical companies and my projects have ranged from target evaluation and early pre-clinical drug development to phase 2 clinical biomarker plan development and implementation.

Greater Seattle Area

Designed and implemented a biomarker plan for a first of its kind phase 2 clinical trial the treatment of type II refractory celiac disease, an in situ intestinal T cell lymphoma, with an anti-IL15 monoclonal antibody. Formulated cell purification and flow cytometry-based analysis of intraepithelial and lamina propria lymphocytes for use across six international sites. Wrote manual and directed training of personnel at each site to ensure uniformity of samples and their analysis for the study. Identified, sourced, and coordinated delivery of reagents to all sites for execution of biomarker plan. Represented Celimmune in interactions with KOLs and technical experts for review of study plans. Provided scientific analysis and assisted in interactions with regulatory agencies in US and Europe. Study recruiting subjects as of April 2016. Also responsible for review, analysis and reporting of data for primary, secondary and exploratory endpoints. Will contribute to clinical report, papers and plans for potential follow on studies.

Seattle, Washington

Responsible for driving the discovery and validation of novel targets in inflammatory and autoimmune disease for the development of innovative medicines. I have collaborated with research scientists at multiple Amgen sites, and work closely with teams in other functional areas including Medical Sciences and Computational Biology. My teams’ work contributed to identification of basic underlying biology and mechanisms driving disease pathogenesis and discovery of novel targets.

Greater Seattle Area

Investigated dendritic cell subsets and their relative dependence on Flt3L or GM-CSF. Work led to the filing of a patent for newly identified C-type lectins.Investigated interaction of dendritic cells with CD4+ and CD8+ T cells and of their relative ability to present or cross-present live or killed virus antigens. Work led to the filing of patents for methods of promoting T cell priming in vivo.

University Of Washington

Studied T cell responses to virus infections and T cell/antigen presenting cell interactions in the laboratory of Michael J. Bevan. Established for the first time that the tremendous expansion of CD8+ T cells seen in response to LCMV infection is almost entirely virus-specific. Findings were published in Immunity and have been widely cited.

Phd, Microbiology

Studied lymphocytic choriomeningitis virus (LCMV)-induced immune exhaustion in the laboratory of Dr Peter J. Southern

Ba, Chemistry

Activities and Societies: Farm House, German House, Ultimate Team, Fencing Team